Spots Global Cancer Trial Database for superficial bladder cancer
Every month we try and update this database with for superficial bladder cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer | NCT01687244 | Superficial Bla... | INSTILADRIN | 18 Years - | FKD Therapies Oy | |
| Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer | NCT03379909 | Superficial Bla... Bladder Cancer | Metformin | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | NCT04752722 | Superficial Bla... Non-muscle Inva... | EG-70 (phase 1) EG-70 (phase 2) | 18 Years - | enGene, Inc. | |
| A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer | NCT00192049 | Superficial Bla... | Gemcitabine mitomycin C | 18 Years - | Eli Lilly and Company | |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | NCT04752722 | Superficial Bla... Non-muscle Inva... | EG-70 (phase 1) EG-70 (phase 2) | 18 Years - | enGene, Inc. | |
| Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk. | NCT00191711 | Superficial Bla... | Gemcitabine | 18 Years - 80 Years | Eli Lilly and Company | |
| Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer | NCT00318643 | Bladder Cancer | Mitomycin C Chemophase | 18 Years - | Halozyme Therapeutics | |
| ADSTILADRIN (=INSTILADRIN) in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) | NCT02773849 | Superficial Bla... | ADSTILADRIN | 18 Years - | Ferring Pharmaceuticals | |
| Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk. | NCT00191711 | Superficial Bla... | Gemcitabine | 18 Years - 80 Years | Eli Lilly and Company | |
| A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | NCT03121768 | Oncology Bladder Cancer Superficial Bla... Recurrence Progression BCG | 18 Years - | Mansoura University | ||
| Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer | NCT00322699 | Superficial Bla... | Whole bladder l... Photofrin | 18 Years - | North Florida/South Georgia Veterans Health System | |
| SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I | NCT02254915 | Urinary Bladder... Urologic Neopla... Urogenital Neop... Neoplasms Neoplasms by Si... Urinary Bladder... Urologic Diseas... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer | NCT01149174 | Superficial Bla... | Mitomycin-C 40 ... | 18 Years - 90 Years | University of Rome Tor Vergata | |
| Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer | NCT00322699 | Superficial Bla... | Whole bladder l... Photofrin | 18 Years - | North Florida/South Georgia Veterans Health System | |
| Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer | NCT02007005 | Superficial Bla... | abnobaVISCUM Fr... | 18 Years - 80 Years | Abnoba Gmbh | |
| Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms | NCT01939756 | Superficial Bla... Lower Urinary T... | Intravesical ba... | 18 Years - 90 Years | University of Rome Tor Vergata | |
| Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer | NCT00318643 | Bladder Cancer | Mitomycin C Chemophase | 18 Years - | Halozyme Therapeutics | |
| Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer | NCT01687244 | Superficial Bla... | INSTILADRIN | 18 Years - | FKD Therapies Oy | |
| A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer | NCT00192049 | Superficial Bla... | Gemcitabine mitomycin C | 18 Years - | Eli Lilly and Company | |
| ADSTILADRIN (=INSTILADRIN) in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) | NCT02773849 | Superficial Bla... | ADSTILADRIN | 18 Years - | Ferring Pharmaceuticals | |
| A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | NCT03121768 | Oncology Bladder Cancer Superficial Bla... Recurrence Progression BCG | 18 Years - | Mansoura University | ||
| Therapeutic Instillation of Mistletoe | NCT02106572 | Superficial Bla... | abnobaVISCUM 90... Mitomycin C | 18 Years - 85 Years | Abnoba Gmbh | |
| Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer | NCT00734994 | Transitional Ce... Superficial Bla... | Hyperthermia Sy... Mitomycin C | 18 Years - 75 Years | Duke University | |
| SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I | NCT02254915 | Urinary Bladder... Urologic Neopla... Urogenital Neop... Neoplasms Neoplasms by Si... Urinary Bladder... Urologic Diseas... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC | NCT01284205 | Bladder Cancer | Mycobacterial C... Bacillus Calmet... | 18 Years - | Bioniche Life Sciences Inc. | |
| First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC | NCT01284205 | Bladder Cancer | Mycobacterial C... Bacillus Calmet... | 18 Years - | Bioniche Life Sciences Inc. | |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | NCT04752722 | Superficial Bla... Non-muscle Inva... | EG-70 (phase 1) EG-70 (phase 2) | 18 Years - | enGene, Inc. | |
| Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer | NCT02007005 | Superficial Bla... | abnobaVISCUM Fr... | 18 Years - 80 Years | Abnoba Gmbh |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
